Amgen (AMGN): FY26 Q2 earnings call, Aug 4, 2026
No Kalshi or Polymarket word markets were listed for Amgen’s Aug 4, 2026 earnings call (FY26 Q2). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
12 matches for “Dazodalibep”; 5 quoted, at least 25 words apart.
…where we are focused on challenging and rare autoimmune diseases with UPLIZNA, dazodalibep, and blinatumomab. UPLIZNA has established the benefit of CD19-directed B-cell depletion in…
…in the U.S. For patients suffering from Sjögren's disease, we are developing dazodalibep. Dazodalibep targets CD40 ligand-mediated signaling between activated T cells and B cells…
…Secondly, are you tracking malignancies on a blinded basis in the ongoing dazodalibep, I always get it wrong, on the CD40 trial? I'd be very…
…and we are very confident in the profile of this medicine. Around dazodalibep, as appropriate for any medicine in phase III clinical investigation, especially immunomodulatory…
…high and potentially associated as well as really any incident effects of the medicine. And we'll learn more about dazodalibep in H2 of this year.
Agents: this page as TSV at /api/v1/appearances/amgen:2026-08-04:earnings_call · words: /api/v1/brief?appearance=amgen:2026-08-04:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP